This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Illumina (ILMN), Nashville Biosciences Partner With Amgen
by Zacks Equity Research
Illumina (ILMN) is currently keeping well with its goals to strengthen its foothold in the multi-billion gene sequencing market globally.
Myriad Genetics (MYGN) Ailed by Mounting Costs, FX Headwind
by Zacks Equity Research
Myriad Genetics' (MYGN) significant gross margin contraction and operating loss as a result of mounting cost pressure are concerning.
Abbott's (ABT) New Launch to Boost Blood Donation Experience
by Zacks Equity Research
Abbott's (ABT) mixed reality offers donors an innovative, immersive digital experience while giving blood.
Here's Why Investors Should Retain SmileDirectClub (SDC) Now
by Zacks Equity Research
Investors are optimistic about SmileDirectClub (SDC) on continued strategic partnerships and expansion in the teledentistry space.
LabCorp (LH) Oncology Arm Gains Traction, Margin Pressure Stays
by Zacks Equity Research
In terms of portfolio enhancement, LabCorp (LH) enters into a collaboration with Becton, Dickinson and Company to advance in life-changing treatments for cancer and other diseases.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Top Research Reports for Caterpillar, Equinor & GSK
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Caterpillar Inc. (CAT), Equinor ASA (EQNR) and GSK plc (GSK).
Here's Why You Should Hold on to Teleflex (TFX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Teleflex (TFX) on strong preference for the UroLift system.
Neogen (NEOG) Q2 Earnings Top Estimates, Gross Margin Up
by Zacks Equity Research
Growth across the Food Safety and Animal Safety segments drives Neogen's (NEOG) Q2 revenues.
Alcon (ALC) Gains From Innovation, Faces FX Challenges
by Zacks Equity Research
Alcon's (ALC) Surgical franchise continues to lead the market with its portfolio of advanced technology, intraocular lenses, a substantial installed base of equipment and a growing consumable base.
AngioDynamics (ANGO) Q2 Earnings, Revenues Top Estimates
by Zacks Equity Research
AngioDynamics (ANGO) registers strong revenue growth in the Med Tech and Med Device businesses in second-quarter fiscal 2023.
Here's Why You Should Retain Ecolab (ECL) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Ecolab (ECL) owing to its strong business.
Bruker's (BRKR) New Tie-Up to Expand Its U.S. CRO Business
by Zacks Equity Research
Bruker's (BRKR) latest partnership is expected to expand its CRO business in the United States, benefiting more biopharma and diagnostics companies using unbiased proteomics for decision-making.
Walgreens Boots (WBA) Q1 Earnings Top, Revenues View Up
by Zacks Equity Research
The U.S. Healthcare segment of Walgreens Boots (WBA) grows on key contract wins, continued partnership growth and a strong focus on execution.
Here's Why You Should Hold Cigna (CI) Stock in Your Portfolio
by Zacks Equity Research
Cigna (CI) remains well-poised for growth on the back of the solid Evernorth and Cigna Healthcare businesses, an expanding customer base and robust cash-generating abilities.
Here's Why You Should Retain Bio-Rad (BIO) Stock for Now
by Zacks Equity Research
Investors are optimistic about Bio-Rad (BIO), led by robust demand in the Life Science and Clinical Diagnostics arms.
Masimo's (MASI) SpHb During Elective CS Favored by New Study
by Zacks Equity Research
Masimo's (MASI) SpHb is likely to indicate clinically acceptable accuracy of Hb measurement even at low Hb levels in patients undergoing CS with antepartum hemorrhage.
Here's Why You Should Retain PacBio (PACB) Stock for Now
by Zacks Equity Research
PacBio's (PACB) strength in its Sequel system raises optimism about the stock.
PETQ vs. BSX: Which Stock Is the Better Value Option?
by Zacks Equity Research
PETQ vs. BSX: Which Stock Is the Better Value Option?
Walgreens (WBA) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Walgreens' (WBA) strategic executions on both the United States and the international front are likely to have contributed to the Q1 2023 top line.
Here's Why You Should Retain CONMED (CNMD) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about CONMED (CNMD) owing to its broad product spectrum.
Here's Why You Should Retain Boston Scientific (BSX) For Now
by Zacks Equity Research
Investors are optimistic about Boston Scientific (BSX), led by new strategic investments and the robust performance of the WATCHMAN device.
PETQ or BSX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PETQ vs. BSX: Which Stock Is the Better Value Option?
Boston Scientific's (BSX) New Buyout to Expand Global Presence
by Zacks Equity Research
Boston Scientific's (BSX) new acquisition deal is expected to strengthen the company's presence in China.
Perrigo (PRGO) Down 1.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.